RU2488582C2 - Бициклозамещенные азопроизводные пиразолона, способ их получения и фармацевтическое применение - Google Patents
Бициклозамещенные азопроизводные пиразолона, способ их получения и фармацевтическое применение Download PDFInfo
- Publication number
- RU2488582C2 RU2488582C2 RU2010127786/04A RU2010127786A RU2488582C2 RU 2488582 C2 RU2488582 C2 RU 2488582C2 RU 2010127786/04 A RU2010127786/04 A RU 2010127786/04A RU 2010127786 A RU2010127786 A RU 2010127786A RU 2488582 C2 RU2488582 C2 RU 2488582C2
- Authority
- RU
- Russia
- Prior art keywords
- compound
- formula
- group
- pharmaceutically acceptable
- acceptable salt
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title claims abstract 4
- 150000001875 compounds Chemical class 0.000 claims abstract 18
- 150000003839 salts Chemical class 0.000 claims abstract 8
- 239000003814 drug Substances 0.000 claims abstract 3
- 238000000034 method Methods 0.000 claims abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 7
- 125000000217 alkyl group Chemical group 0.000 claims 5
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims 4
- 229910052799 carbon Inorganic materials 0.000 claims 4
- 150000001721 carbon Chemical group 0.000 claims 3
- 206010043554 thrombocytopenia Diseases 0.000 claims 3
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 229940126460 thrombopoietin receptor agonist Drugs 0.000 claims 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N N-phenyl amine Natural products NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- -1 aniline compound Chemical class 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 125000005047 dihydroimidazolyl group Chemical group N1(CNC=C1)* 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- XYIBRDXRRQCHLP-UHFFFAOYSA-N ethyl acetoacetate Chemical compound CCOC(=O)CC(C)=O XYIBRDXRRQCHLP-UHFFFAOYSA-N 0.000 claims 1
- 125000002541 furyl group Chemical group 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 125000000168 pyrrolyl group Chemical group 0.000 claims 1
- 125000003831 tetrazolyl group Chemical group 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- 102000036693 Thrombopoietin Human genes 0.000 abstract 2
- 108010041111 Thrombopoietin Proteins 0.000 abstract 2
- 102000005763 Thrombopoietin Receptors Human genes 0.000 abstract 1
- 108010070774 Thrombopoietin Receptors Proteins 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 0 *c(cc1C2NC2)cc(*)c1O* Chemical compound *c(cc1C2NC2)cc(*)c1O* 0.000 description 2
- SCGDITKQRLKVKV-JVCXMKTPSA-N CC(CC1)c2c1ccc(N(C1=O)N=C(C)/C1=N/Nc(cc(C)cc1-c3cccc(C(O)=O)c3)c1O)c2 Chemical compound CC(CC1)c2c1ccc(N(C1=O)N=C(C)/C1=N/Nc(cc(C)cc1-c3cccc(C(O)=O)c3)c1O)c2 SCGDITKQRLKVKV-JVCXMKTPSA-N 0.000 description 1
- VGRPINLOMRZVAY-OLFWJLLRSA-N CC(CC1)c2c1ccc(N(C1=O)N=C(C)/C1=N/Nc(cccc1-c3cccc(C(O)=O)c3)c1O)c2 Chemical compound CC(CC1)c2c1ccc(N(C1=O)N=C(C)/C1=N/Nc(cccc1-c3cccc(C(O)=O)c3)c1O)c2 VGRPINLOMRZVAY-OLFWJLLRSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D231/08—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with oxygen or sulfur atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
- C07D231/20—One oxygen atom attached in position 3 or 5
- C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200810000346.6 | 2008-01-10 | ||
| CNA2008100003466A CN101481352A (zh) | 2008-01-10 | 2008-01-10 | 双环取代吡唑酮偶氮类衍生物、其制备方法及其在医药上的应用 |
| PCT/CN2009/000001 WO2009092276A1 (zh) | 2008-01-10 | 2009-01-04 | 双环取代吡唑酮偶氮类衍生物、其制备方法及其在医药上的应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2010127786A RU2010127786A (ru) | 2012-02-20 |
| RU2488582C2 true RU2488582C2 (ru) | 2013-07-27 |
Family
ID=40878665
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2010127786/04A RU2488582C2 (ru) | 2008-01-10 | 2009-01-04 | Бициклозамещенные азопроизводные пиразолона, способ их получения и фармацевтическое применение |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US8367710B2 (enExample) |
| EP (1) | EP2236500B1 (enExample) |
| JP (1) | JP5441269B2 (enExample) |
| KR (1) | KR101556808B1 (enExample) |
| CN (2) | CN101481352A (enExample) |
| AU (1) | AU2009207966B2 (enExample) |
| BR (1) | BRPI0907234B1 (enExample) |
| CA (1) | CA2711535C (enExample) |
| ES (1) | ES2533366T3 (enExample) |
| MX (1) | MX2010007553A (enExample) |
| PT (1) | PT2236500E (enExample) |
| RU (1) | RU2488582C2 (enExample) |
| UA (1) | UA101172C2 (enExample) |
| WO (1) | WO2009092276A1 (enExample) |
| ZA (1) | ZA201004794B (enExample) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2538977C2 (ru) * | 2009-06-11 | 2015-01-10 | Цзянсу Хэнжуй Медицин Ко., Лтд. | Соли бициклозамещенных производных азопиразолона, способ их получения и применение |
| RU2733844C2 (ru) * | 2016-01-22 | 2020-10-07 | Цзянсу Хэнжуй Медицин Ко., Лтд. | Фармацевтическая композиция, включающая бициклозамещенное азопроизводное пиразолона или его соль, и способ их получения |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0302486D0 (sv) * | 2003-09-18 | 2003-09-18 | Astrazeneca Ab | Novel compounds |
| EP2492262B1 (en) * | 2009-10-23 | 2016-04-20 | Nissan Chemical Industries, Ltd. | Fused heterocyclic compound and thrombopoietin receptor activator |
| CN103360317B (zh) * | 2012-04-11 | 2016-12-14 | 齐鲁制药有限公司 | 双环取代吡唑酮偶氮类衍生物、其制备方法及用途 |
| CN103724206A (zh) * | 2014-01-17 | 2014-04-16 | 青岛农业大学 | 化合物2-溴-4-氟-6-硝基苯酚的制备方法和农用生物活性 |
| WO2015111085A2 (en) * | 2014-01-27 | 2015-07-30 | Cadila Healthcare Limited | Processes for the preparation of eltrombopag and pharmaceutically acceptable salts, solvates and intermediates thereof |
| EP3116469B1 (en) | 2014-03-10 | 2018-10-03 | Mary Kay, Inc. | Skin lightening compositions |
| CN104592033A (zh) * | 2014-12-30 | 2015-05-06 | 杭州和泽医药科技有限公司 | 一种艾曲波帕关键中间体的合成方法 |
| CN106994120B (zh) * | 2016-01-22 | 2021-05-14 | 江苏恒瑞医药股份有限公司 | 一种含有双环取代吡唑酮偶氮类衍生物或其盐的药物组合物及其制备方法 |
| WO2018133818A1 (zh) * | 2017-01-19 | 2018-07-26 | 江苏恒瑞医药股份有限公司 | 一种双环取代吡唑酮偶氮类衍生物的制备方法及其中间体 |
| CN110028497B (zh) * | 2018-01-11 | 2020-11-17 | 江苏恒瑞医药股份有限公司 | 一种血小板生成素模拟物的乙醇胺盐的结晶形式及制备方法 |
| US20220071961A1 (en) * | 2019-01-08 | 2022-03-10 | Jiangsu Hengrui Medicine Co., Ltd. | Dosing Regimen of Bicyclic Substituted Pyrazolone Azo Derivative |
| CN112062699B (zh) * | 2020-11-13 | 2021-02-26 | 苏州开元民生科技股份有限公司 | 一种邻氨基苯硫酚的制备方法 |
| WO2022228551A1 (zh) * | 2021-04-30 | 2022-11-03 | 江苏恒瑞医药股份有限公司 | 一种血小板生成素受体激动剂的给药方案 |
| WO2023143364A1 (zh) * | 2022-01-25 | 2023-08-03 | 江苏恒瑞医药股份有限公司 | 一种血小板生成素受体激动剂的给药方案 |
| WO2025140275A1 (zh) * | 2023-12-25 | 2025-07-03 | 江苏恒瑞医药股份有限公司 | 取代吡唑啉偶氮衍生物的磷酸酯化合物或其可药用盐 |
| CN120383561A (zh) * | 2025-03-26 | 2025-07-29 | 浙江本立科技股份有限公司 | 一种三氯甲基喹啉和2-取代乙酸联产喹啉酰氯和2-取代乙酰氯的方法 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2284994C2 (ru) * | 2002-05-22 | 2006-10-10 | Смитклайн Бичам Корпорейшн | Бис-(моноэтаноламин) 3`-[(2z)-[1-(3,4-диметилфенил)-1,5-дигидро-3-метил-5-оксо-4h-пиразол-4-илиден] гидразино]-2`-гидрокси-[1,1`-бифенил]-3-карбоновой кислоты |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB775216A (en) * | 1954-02-23 | 1957-05-22 | Sandoz Ltd | Improvements in or relating to monoazo dyestuffs of the benzene-azo-pyrazolone series and their chromium-complex compounds |
| GB806709A (en) * | 1955-04-22 | 1958-12-31 | Bayer Ag | Monoazo dyestuffs of the benzene-azo-pyrazolone series and metal complexes thereof |
| US5869451A (en) | 1995-06-07 | 1999-02-09 | Glaxo Group Limited | Peptides and compounds that bind to a receptor |
| CN1966520B (zh) | 1995-06-07 | 2012-07-11 | 葛兰素集团有限公司 | 结合血小板生成素受体的肽和化合物 |
| JPH111477A (ja) | 1997-06-12 | 1999-01-06 | Hokuriku Seiyaku Co Ltd | １，４−ベンゾジアゼピン誘導体及びその用途 |
| WO1999011262A1 (en) | 1997-09-02 | 1999-03-11 | Roche Diagnostics Gmbh | Mpl-receptor ligands, process for their preparation, medicaments containing them and their use for the treatment and prevention of thrombocytopaenia and anaemia |
| EP1133291B1 (en) | 1998-11-17 | 2006-01-11 | Smithkline Beecham Corporation | Cyclic polyamines for treating thrombocytopenia |
| EP1141909B1 (de) | 1998-12-14 | 2002-09-04 | Vodafone AG | Verfahren zur übertragung von verkehrsinformationen |
| GC0000177A (en) | 1998-12-17 | 2006-03-29 | Smithkline Beecham | Thrombopoietin mimetics |
| KR20020069183A (ko) | 1999-07-26 | 2002-08-29 | 시오노기세이야쿠가부시키가이샤 | 트롬보포이에틴 작동성을 나타내는 의약 조성물 |
| AU770564B2 (en) | 1999-09-10 | 2004-02-26 | Smithkline Beecham Corporation | Thrombopoietin mimetics |
| JP2003513965A (ja) | 1999-11-05 | 2003-04-15 | スミスクライン・ビーチャム・コーポレイション | セミカルバゾン誘導体およびそれらのトロンボポエチン模倣物としての使用 |
| DE60031714T2 (de) | 1999-12-06 | 2007-09-06 | Smithkline Beecham Corp. | Thrombopoietin-mimetika |
| TWI284639B (en) | 2000-01-24 | 2007-08-01 | Shionogi & Co | A compound having thrombopoietin receptor agonistic effect |
| CY2010012I2 (el) * | 2000-05-25 | 2020-05-29 | Novartis Ag | Μιμητικα θρομβοποιητινης |
| EP1622609A4 (en) * | 2003-04-29 | 2008-09-03 | Smithkline Beecham Corp | METHODS OF TREATING DEGENERATIVE DISEASES / LESIONS |
| EP1701934B1 (en) | 2003-12-26 | 2009-02-25 | Allergan, Inc. | DISUBSTITUTED CHALCONE OXIMES HAVING RAR(Gamma)-RETINOID RECEPTOR ANTAGONIST ACTIVITY |
| JP4518819B2 (ja) * | 2004-03-17 | 2010-08-04 | 富士フイルム株式会社 | アゾ化合物 |
| KR101215207B1 (ko) | 2004-12-14 | 2012-12-26 | 닛산 가가쿠 고교 가부시키 가이샤 | 아미드 화합물 및 트롬보포이에틴 리셉터 활성화제 |
| WO2007044982A2 (en) * | 2005-10-13 | 2007-04-19 | Smithkline Beecham Corporation | Methods for the preservation of platelet efficacy during storage |
| CA2630234A1 (en) * | 2005-11-23 | 2007-05-31 | Ligand Pharmaceuticals Inc. | Thrombopoietin activity modulating compounds and methods |
-
2008
- 2008-01-10 CN CNA2008100003466A patent/CN101481352A/zh active Pending
-
2009
- 2009-01-04 CA CA2711535A patent/CA2711535C/en active Active
- 2009-01-04 WO PCT/CN2009/000001 patent/WO2009092276A1/zh not_active Ceased
- 2009-01-04 MX MX2010007553A patent/MX2010007553A/es active IP Right Grant
- 2009-01-04 KR KR1020107017630A patent/KR101556808B1/ko active Active
- 2009-01-04 JP JP2010541680A patent/JP5441269B2/ja active Active
- 2009-01-04 US US12/812,119 patent/US8367710B2/en active Active
- 2009-01-04 UA UAA201008616A patent/UA101172C2/ru unknown
- 2009-01-04 ES ES09703490.4T patent/ES2533366T3/es active Active
- 2009-01-04 PT PT97034904T patent/PT2236500E/pt unknown
- 2009-01-04 CN CN2009800001980A patent/CN101679286B/zh active Active
- 2009-01-04 RU RU2010127786/04A patent/RU2488582C2/ru active
- 2009-01-04 BR BRPI0907234-9A patent/BRPI0907234B1/pt active IP Right Grant
- 2009-01-04 AU AU2009207966A patent/AU2009207966B2/en active Active
- 2009-01-04 EP EP09703490.4A patent/EP2236500B1/en active Active
-
2010
- 2010-07-07 ZA ZA2010/04794A patent/ZA201004794B/en unknown
-
2013
- 2013-01-16 US US13/742,633 patent/US20130123507A1/en not_active Abandoned
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2284994C2 (ru) * | 2002-05-22 | 2006-10-10 | Смитклайн Бичам Корпорейшн | Бис-(моноэтаноламин) 3`-[(2z)-[1-(3,4-диметилфенил)-1,5-дигидро-3-метил-5-оксо-4h-пиразол-4-илиден] гидразино]-2`-гидрокси-[1,1`-бифенил]-3-карбоновой кислоты |
Non-Patent Citations (1)
| Title |
|---|
| LIDIA MOREIRA LIMA AND ELIEZER J. BARREIRO "Bioisosterism: A Useful Strategy for Molecular Modification and Drug Design", Current Medicinal Chemistry, 2005, 12, p.p.23-49. * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2538977C2 (ru) * | 2009-06-11 | 2015-01-10 | Цзянсу Хэнжуй Медицин Ко., Лтд. | Соли бициклозамещенных производных азопиразолона, способ их получения и применение |
| RU2733844C2 (ru) * | 2016-01-22 | 2020-10-07 | Цзянсу Хэнжуй Медицин Ко., Лтд. | Фармацевтическая композиция, включающая бициклозамещенное азопроизводное пиразолона или его соль, и способ их получения |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20100120141A (ko) | 2010-11-12 |
| EP2236500A1 (en) | 2010-10-06 |
| AU2009207966A1 (en) | 2009-07-30 |
| US8367710B2 (en) | 2013-02-05 |
| CA2711535C (en) | 2015-12-15 |
| US20100316601A1 (en) | 2010-12-16 |
| KR101556808B1 (ko) | 2015-10-01 |
| ZA201004794B (en) | 2011-09-28 |
| AU2009207966B2 (en) | 2013-03-21 |
| BRPI0907234B1 (pt) | 2021-08-10 |
| BRPI0907234A2 (pt) | 2020-08-04 |
| CA2711535A1 (en) | 2009-07-30 |
| EP2236500B1 (en) | 2014-12-24 |
| US20130123507A1 (en) | 2013-05-16 |
| MX2010007553A (es) | 2010-10-04 |
| RU2010127786A (ru) | 2012-02-20 |
| CN101679286A (zh) | 2010-03-24 |
| JP2011509263A (ja) | 2011-03-24 |
| JP5441269B2 (ja) | 2014-03-12 |
| CN101481352A (zh) | 2009-07-15 |
| EP2236500A4 (en) | 2012-08-22 |
| ES2533366T3 (es) | 2015-04-09 |
| CN101679286B (zh) | 2011-06-08 |
| WO2009092276A1 (zh) | 2009-07-30 |
| UA101172C2 (ru) | 2013-03-11 |
| HK1134818A1 (en) | 2010-05-14 |
| PT2236500E (pt) | 2015-04-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2363700C2 (ru) | Производные хинуклидина и фармацевтические композиции, содержащие их | |
| RU2016139352A (ru) | Способ получения [(3-гидроксипиридин-2-карбонил)амино]алкановых кислот, сложных эфиров и амидов | |
| WO2008083056A3 (en) | Ligands for imaging cardiac innervation | |
| JP2018511647A5 (enExample) | ||
| MY142807A (en) | Benzimidazole derivative and use thereof. | |
| JP2010138190A5 (enExample) | ||
| RU2016108987A (ru) | Замещенные бензоазепины в качестве модуляторов toll-подобного рецептора | |
| RU2010127786A (ru) | Бициклозамещенные азопроизводные пиразолона, способ их получения и фармацевтическое применение | |
| JP2009532453A5 (enExample) | ||
| JP2010504286A5 (enExample) | ||
| WO2008057862A3 (en) | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-ϰB ACTIVITY AND USE THEREOF | |
| RU2015105825A (ru) | Композиция для борьбы с болезнями растений и ее применение | |
| BRPI0507005A (pt) | compostos, composições farmacêuticas, uso de um composto, e, método de preparo de uma composição farmacêutica | |
| RU2013107007A (ru) | Бифункциональные соединения, являющиеся ингибиторами rho-киназы, композиция и применение | |
| RU2012123154A (ru) | Способы лечения синдрома фибромиалгии | |
| EA200901573A1 (ru) | Гетероарилзамещенные тиазолы | |
| JP2005526836A5 (enExample) | ||
| JP2015501820A5 (enExample) | ||
| RU2018109925A (ru) | Галогензамещенное гетероциклическое соединение | |
| RU2012105122A (ru) | Способ получения хиральных производных 3-триазолилсульфоксида | |
| RU2013138372A (ru) | Производные азетидина, применяемые для лечения метаболических и воспалительных заболеваний | |
| RU2011112684A (ru) | АГЕНТ, СПОСОБСТВУЮЩИЙ РОСТУ ВОЛОС, СОДЕРЖАЩИЙ В КАЧЕСТВЕ АКТИВНОГО ИНГРЕДИЕНТА ПРОИЗВОДНОЕ 15,15-ДИФТОРПРОСТАГЛАНДИНА F2α | |
| JP2013537240A5 (enExample) | ||
| RU2009102270A (ru) | Производные тиазолилмочевины в качестве ингибиторов фосфатидилинозитол-3-киназы | |
| BRPI0409049A (pt) | métodos de preparação de um composto, composição e composição cristalina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| TK4A | Correction to the publication in the bulletin (patent) |
Free format text: AMENDMENT TO CHAPTER -FG4A- IN JOURNAL: 21-2013 FOR TAG: (57) |